The 3 stocks attempting to buck their downtrends

Canopy Growth Corporation, Adaptive Biotechnologies Corporation, CRISPR Therapeutics AG are currently leading the list of down-trending stocks.

Leading equity indices in the US rose as S&P 500 closed the day at 4,450.38, having gained 1.23%. Nasdaq ended the session at 13,800 after a 1.45% gain.

What is a downtrend?

The perceived tendency of a price to move in a downward direction over time. A downtrend describes the price movement of a continously depreciative financial asset over a particular time frame. In a downtrend, each successive low and peak is lower than the ones found earlier in the trend. The downtrend is therefore composed of lower swing lows and lower swing highs.

Canopy Growth continues a 14 day downtrend; dips 11.38% Friday

After setting a 38.4 cents – 43 cents range, Canopy Growth Corporation closed the day 11.38% lower at 38.79 cents. After ending Thursday at 43.77 cents, Canopy Growth dropped to 38.4 cents early in Friday's session and closed at 38.79 cents. In total, it lost 11.38%. Daily trading volume (29.29 million shares) increased, making up 214% of the 21-day average (13.69 million).

| Adaptive Biotechnologies | continues a 13 day decline; stumbles 1.61% Friday

After setting a $6.7 – $7 range, Adaptive Biotechnologies closed the day 1.61% lower at $6.71. Grinding lower but with no clear-cut direction, the immune-driven medicine pioneer closed the session at $6.71 after forming a distinct $6.7 – $7 range. Trading volume totalled 631,529 which equates to around 57% of the stock's 21-day average Friday.

CRISPR Therapeutics continues a 27 day downtrend; withdraws 1.54% Friday

Friday's session continued the recent downtrend: early in Friday's session, CRISPR Therapeutics dropped to $55.83 from $57.02 at the end of Thursday, before closing at $56.14. During the session, it lost 1.54%. After setting a $55.83 – $58 range, CRISPR Therapeutics closed the day 1.54% lower at $56.14. Trading volume totalled 1 million which equates to around 86% of the stock's 21-day average Friday.

The company's market cap currently stands at $4.43 billion with an average daily trading volume of 1.28 million shares. The Swiss biotechnology company now trading 23.66% above its 3-month low of $39.19. So far this year, it has been outperforming the Nasdaq by 11.13%. Trending downwards for around a month.